WuXi Biologics (Cayman) Inc. (HKG:2269)
23.40
-0.30 (-1.27%)
May 28, 2025, 4:08 PM HKT
WuXi Biologics Revenue
In the year 2024, WuXi Biologics had annual revenue of 18.68B CNY with 9.63% growth. WuXi Biologics had revenue of 10.10B in the half year ending December 31, 2024, with 25.29% growth.
Revenue
18.68B CNY
Revenue Growth
+9.63%
P/S Ratio
4.79
Revenue / Employee
1.49M CNY
Employees
12,575
Market Cap
95.12B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 18.68B | 1.64B | 9.63% |
Dec 31, 2023 | 17.03B | 1.77B | 11.56% |
Dec 31, 2022 | 15.27B | 4.98B | 48.38% |
Dec 31, 2021 | 10.29B | 4.68B | 83.35% |
Dec 31, 2020 | 5.61B | 1.63B | 40.88% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 32.53B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
Innovent Biologics | 10.03B |
CSPC Pharmaceutical Group | 30.87B |
Sino Biopharmaceutical | 30.72B |
Akeso | 2.26B |
Alibaba Health Information Technology | 32.81B |
WuXi Biologics News
- 10 days ago - WuXi Biologics: Eyes On Long-Term Risks And Near-Term Outlook (Rating Downgrade) - Seeking Alpha
- 11 days ago - WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA - PRNewsWire
- 4 weeks ago - Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report - PRNewsWire
- 5 weeks ago - WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year - PRNewsWire
- 5 weeks ago - WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou ... - GuruFocus
- 5 weeks ago - WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site - PRNewsWire
- 6 weeks ago - WuXi Biologics Wins Five Asia-Pacific Biopharma Excellence Awards - PRNewsWire
- 2 months ago - Wuxi Biologics ADR reports FY results - Seeking Alpha